ASSESSING PHARMACOTHERAPEUTIC MANAGEMENT OF ANEMIA IN VARIOUS STAGES OF CHRONIC KIDNEY DISEASE AND POST RENAL TRANSPLANT PATIENTS

Introduction: Anemia in CKD occurs when the kidneys are damaged or diseased. They cannot make enough EPO, which stimulates the bone marrow to produce RBC. It is associated with increased cardiovascular diseases, hospitalization, reduced quality of life, cognitive impairment, and mortality. Materials and Methods: A prospective observational study was conducted on CKD patients. Demographic details, treatment information, SES, and performance of daily activities were collected from the patients. Anemia was confirmed in patients by observing laboratory investigations, SES was collected by using the Modified Kuppuswamy scale, and the performance of patients for the treatment was analyzed by using the Karnofsky performance index. Results: The majority of the patients affected with anemia belong to UL Class. The performance of patients was improved as well as an increase in hemoglobin levels and decreases in Serum Creatinine levels were observed. P-value calculated for Haemoglobin, and serum creatinine was < 0.0001, which indicates the treatment was statistically significant. Conclusion: The pharmacotherapeutic treatment prescribed for anemia in various categories of CKD patient’s shows significant improvement in the levels of Haemoglobin and serum creatinine.